Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DSGN vs SVRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SVRA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)
SVRA Overall Winner
6-Pillar Tally: DSGN 2 – 3 SVRA (1 Tie)
Matrix Metrics: DSGN 3 – 4 SVRA
As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas SVRA carries 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile SVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DSGN vs SVRA
DSGN
Design Therapeutics, Inc. Common Stock
$9.94
-5.06% 1D
Market Cap
$677.5M
TTM Revenue
$33,000
Forward P/E
N/M
Beta / 30D Vol
1.32β · 61% Vol
Unified Composite Score
49.9
HOLD
Tech 55.0
Fund 56.0
Flow 63.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
SVRA
Head-to-Head Winner
Savara Inc.
$4.42
-4.63% 1D
Market Cap
$1.1B
TTM Revenue
$1,000
Forward P/E
0.4x
Beta / 30D Vol
1.48β · 73% Vol
Unified Composite Score
57.7
HOLD
Tech 42.0
Fund 54.0
Flow 70.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DSGN 2 – 3 SVRA)
1. Valuation Multiples
SVRA
Forward P/E
N/M
0.4x
Trailing P/E
N/M
0.4x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
N/M
2. Growth & Scale
SVRA
Revenue Growth (YoY)
+0.0%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$33,000
$1,000
Market Cap
$677.5M
$1.1B
3. Profitability & Quality
DSGN
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-36.9%
-151.0%
4. Balance Sheet & Cash Flow
DSGN
Cash Generation (TTM)
-$59M
-$131M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$13M Net Cash
$551,000 Net Debt (0.28x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
SVRA
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
92.0% (13th %ile)
164.3% (17th %ile)
Put/Call OI Skew
N/A
0.05x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DSGN (3) vs SVRA (4)| Institutional Metric | DSGN | SVRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $677.5M | $1.1B | SVRA | |
| Trailing P/E Ratio | N/M | 0.4x | SVRA | |
| Forward P/E Ratio | N/M | 0.4x | SVRA | |
| Revenue Growth (YoY) | +0.0% | +0.0% | Tie | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -36.9% | -151.0% | DSGN | |
| 52-Week Range Position | 30% ($7–$17) | 13% ($4–$7) | DSGN | |
| Beta / 30D Volatility | 1.32β · 61% Vol | 1.48β · 73% Vol | DSGN | |
| Unified Institutional Score | 49.9 / 100 (HOLD) | 57.7 / 100 (HOLD) | SVRA | |
| Trailing 12M Revenue (USD) | $33,000 | $1,000 | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$59M ($13M Net Cash) | -$131M ($551,000 Net Debt (0.28x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SVRA +3.03 pp
3M Horizon
SVRA +17.31 pp
6M Horizon
DSGN +2.78 pp
1Y Horizon
DSGN +36.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DSGN Revenue | SVRA Revenue | DSGN Op. Margin | SVRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2010 | N/A | $0M | N/A | -1746.5% | SVRA |
| FY2015 | N/A | $0M | N/A | -10968.5% | SVRA |
| FY2016 | N/A | $0M | N/A | -2737.0% | SVRA |
| FY2020 | $0M | $0M | -3685.8% | -19182.9% | DSGN |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DSGN
BREAKDOWN
Current IV
92.0%
IV Percentile
13th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DSGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
SVRA
BREAKDOWN
Current IV
164.3%
IV Percentile
17th %ile
Put/Call OI Skew
0.05x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact SVRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DSGN Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
SVRA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DSGN vs SVRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Savara Inc. (SVRA) is the stronger overall head-to-head candidate over Design Therapeutics, Inc. (DSGN) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). DSGN carries a Unified Composite Score of 49.9/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin), whereas SVRA carries 57.7/100 (HOLD) at $4.42 (0.4x Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: DSGN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 41.4); meanwhile SVRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SVRA leads the Growth & Scale pillar: DSGN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $33,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with SVRA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, 0.0% operating margin). Across the 4-period historical trajectory (FY2010 to FY2020), DSGN cumulative revenue shifted N/A while SVRA shifted N/A. In operating R&D and SG&A reinvestment, DSGN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SVRA.
SVRA screens cheaper on headline valuation multiples. DSGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SVRA trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DSGN (-36.9% ROE) versus SVRA (-151.0% ROE) capital efficiency.
In options market volatility and institutional positioning, DSGN carries 92.0% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 61% Vol realized risk). By comparison, SVRA carries 164.3% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.48β · 73% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
SVRA vs DSGN · Reverse Pair
DSGN vs CGEM
· Sector Peer
DSGN vs EWTX
· Sector Peer
DSGN vs IMCR
· Sector Peer
SVRA vs AQST
· Sector Peer
SVRA vs SLDB
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem